Advances in Rare Diseases: Hemophilia

WuXi AppTec is pleased to invite you to join us for the second session of our webinar series “Collaborations That Transform,” highlighting the impact of partnerships in bringing effective therapies to patients. This complimentary webinar, to be broadcast worldwide on July 16, will convene leading physicians, drug developers, patients and advocates. These experts will discuss the latest advances in the development of transformative medicines for hemophilia, including gene therapy and next generation technologies.

Hemophilia is a rare genetic bleeding disorder in which blood does not clot properly, leading to a number of painful and potentially fatal complications. According to National Hemophilia Foundation, approximately 75% of people with hemophilia around the world still receive inadequate treatment or have no access to treatment. There is currently no cure for hemophilia.

As an enabler of the biotech and medical device industry, WuXi AppTec shares the conviction that we must work collaboratively to solve industry-wide problems and bring transformational medicines to people living with rare diseases. Our July 16 webinar will continue the dynamic discussions that began with WuXi AppTec’s inaugural rare disease webinar in May. It is complimentary and open to the public.

We welcome you to join the conversation.

We would like to thank BioCentury, Children’s Tumor Foundation, CLSA, Informa, New England Hemophilia Association and UK Bioindustry Association for their great support of the “Collaborations That Transform” webinar series.